CDMO Ritedose Corporation announced that it will manufacture Verona Pharma’s Ohtuvayre nebulized ensifentrine, which was approved by the FDA in June 2024 for the treatment of COPD. Also in June 2024, Ritedose announced that it was adding blow-fill-seal (BFS) capacity for an additional 180 million unit doses at its manufacturing facility in Columbia, SC, USA.
Ritedose President and CEO Jody Chastain commented, “Ritedose is the leading manufacturer of inhaled products for asthma and COPD. We are proud to partner with Verona Pharma for the development and manufacturing of Ohtuvayre. We have served the respiratory market for over 25 years and are excited to help bring this novel therapy to commercialization. We have the resources to deliver significant doses of Ohtuvayre on time, every time.”
Verona Pharma President and CEO David Zaccardelli said, “Ohtuvayre is a significant advancement in the treatment of COPD. We believe Ohtuvayre’s novel profile can change the treatment paradigm for COPD, and we wanted to partner with Ritedose to ensure the highest manufacturing quality. The COPD community deserves nothing less.”
Read the Ritedose press release.
